OCULAR THERAPEUTIX, INC Total Revenue

• OCULAR THERAPEUTIX, INC showed a decrease of -18.5% in Total Revenue from 2024 to 2025.
• This data is from OCULAR THERAPEUTIX, INC's annual report (Form 10-K), filed with the SEC on February 5, 2026.
• XBRL data for this metric is available from 2016 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2017: $475.0 thousand | Q2 2017: $438.0 thousand | Q3 2017: $523.0 thousand | Q4 2017: $487.0 thousand | Q1 2018: $340.0 thousand | Q1 2018: $340.0 thousand | Q2 2018: $648.0 thousand | Q2 2018: $648.0 thousand | Q3 2018: $498.0 thousand | Q3 2018: $498.0 thousand | Q4 2018: $504.0 thousand | Q4 2018: $504.0 thousand | Q1 2019: $492.0 thousand | Q2 2019: $650.0 thousand | Q3 2019: $829.0 thousand | Q4 2019: $2.26 million | Q1 2020: $2.61 million | Q2 2020: $1.57 million | Q3 2020: $5.88 million | Q1 2021: $7.34 million | Q2 2021: $11.72 million | Q3 2021: $12.15 million | Q1 2022: $13.19 million | Q2 2022: $12.27 million | Q3 2022: $11.97 million | Q1 2023: $13.37 million | Q2 2023: $15.19 million | Q3 2023: $15.08 million | Q1 2024: $14.77 million | Q2 2024: $16.44 million | Q3 2024: $15.43 million | Q1 2025: $10.70 million | Q2 2025: $13.46 million | Q3 2025: $14.54 million.
• Over the full 12 years of available data (2016 to 2025), OCULAR THERAPEUTIX, INC's Total Revenue has grown by 2,653.1%.
• Historical annual values: Fiscal year 2025: $51.95 million | Fiscal year 2024: $63.72 million | Fiscal year 2023: $58.44 million | Fiscal year 2022: $51.49 million | Fiscal year 2021: $43.52 million | Fiscal year 2020: $17.40 million | Fiscal year 2019: $4.23 million | Fiscal year 2018: $1.99 million | Fiscal year 2018: $1.99 million | Fiscal year 2017: $1.92 million | Fiscal year 2017: $1.92 million | Fiscal year 2016: $1.89 million.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026